We analyzed CyTOF data from the Early AMPLE trial (ClinicalTrials.gov: NCT02557100), a randomized, head-to-head, single-blind study comparing abatacept (CTLA4Ig) and adalimumab (anti-TNF) in new-onset RA (16). Here, TNF is linked to rheumatoid arthritis.